Not all GLP-1 drugs work the same way.
| Stat | Value |
|---|---|
| Lixisenatide duration — works primarily at mealtimes, not all-day | Short-acting |
| Typical weight loss with lixisenatide vs. 6–22%+ with semaglutide/tirzepatide | ~2–3 kg |
| Lixisenatide's key clinical trial program (13 trials) | GETGOAL |
| Sanofi/Regeneron triple agonist pipeline compound | SAR441255 |
Key Takeaways
- What it is: Lixisenatide (Adlyxin) is a once-daily, short-acting GLP-1 receptor agonist approved for type 2 diabetes in the U.S. in 2016.
- Mechanism difference: Short-acting GLP-1 agonists produce a stronger effect on post-meal glucose (gastric emptying slowdown) than fasting glucose; long-acting drugs like semaglutide do both.
- Weight loss reality: Lixisenatide produces modest weight loss (~2–3 kg) — not competitive with semaglutide or tirzepatide.
- Where it still fits: Patients who need targeted post-meal glucose control with a potentially milder GI side effect profile than long-acting GLP-1s.
- Sanofi's pipeline: SAR441255, developed with Regeneron, is a triple GLP-1/GIP/glucagon agonist — placing Sanofi in the next-generation weight loss space even if Adlyxin isn't.
- Honest verdict: Adlyxin is not a weight loss drug in any competitive sense. Understanding why helps clarify the entire GLP-1 class.
If your prescriber or a clinical article mentions Sanofi and GLP-1 in the same sentence, there's a good chance you'll encounter lixisenatide (brand name: Adlyxin). It's worth understanding — not because it's the drug you're likely to take, but because it occupies a unique mechanistic position in the GLP-1 class that explains a lot about how these drugs differ from one another.
What Lixisenatide Is and How It Works
Lixisenatide is a GLP-1 receptor agonist — the same receptor target as semaglutide.
The key difference is duration. Semaglutide is long-acting: it's engineered to stay in your bloodstream for about a week, producing continuous GLP-1 receptor stimulation around the clock. Lixisenatide is short-acting: administered once daily, it produces a peak of GLP-1 activity in the hours following the injection, then clears relatively quickly.
That duration difference changes what the drug actually does in clinical practice. Long-acting GLP-1 agonists suppress appetite continuously, reduce fasting glucose, slow gastric emptying throughout the day, and send persistent satiety signals to the brain. Short-acting drugs like lixisenatide produce a pronounced effect on post-meal (postprandial) glucose — particularly through gastric emptying slowdown — without the sustained 24-hour receptor activation.
In type 2 diabetes management, postprandial glucose control matters. Many T2D patients have glucose spikes after meals that are disproportionate to their fasting glucose levels. A drug that specifically targets that spike can be a useful tool even without the all-day satiety and fasting glucose effects of longer-acting options.
The GETGOAL Trials: What the Clinical Data Shows
Sanofi built the GETGOAL program to establish lixisenatide's evidence base.
The GETGOAL program included 13 trials across a range of patient populations and background medication regimens. The consistent finding: lixisenatide reduced HbA1c by approximately 0.7–0.9% from baseline, with a specific strength in attenuating post-meal glucose excursions. When compared to other GLP-1 agonists in head-to-head analyses, lixisenatide generally performed similarly on HbA1c reduction but delivered notably less weight loss.
Weight loss averaged roughly 2–3 kg across GETGOAL trials — meaningful compared to placebo, but a fraction of what semaglutide (up to 15% body weight with Wegovy) or tirzepatide (up to 22.5% with Zepbound) achieves. This wasn't a trial design problem; it reflects the pharmacology. A drug that works primarily at mealtimes simply doesn't produce the sustained appetite suppression that drives major weight loss.
The ELIXA trial — the cardiovascular outcomes trial for lixisenatide — showed the drug was cardiovascularly neutral: it didn't increase CV risk (important after early concerns about another diabetes drug class), but it also didn't show the CV benefit seen in the LEADER trial with Victoza or the SUSTAIN-6 trial with Ozempic. Neutral cardiovascular data is a pass, not a selling point.
Why Lixisenatide Is Rarely Prescribed in 2026
Prescribers aren't avoiding Adlyxin because it doesn't work.
They're prescribing semaglutide and tirzepatide instead because those drugs do more — and they have outcomes data to justify it. When a T2D patient needs blood sugar control and also wants to lose weight (which is most T2D patients), there's a straightforward case for reaching for a drug that delivers both rather than a drug that delivers one adequately and the other modestly.
The GI side effect argument — that short-acting GLP-1s might be better tolerated — is real but limited in practice. Nausea and GI discomfort are common with all GLP-1 receptor agonists, especially early in treatment. The dose escalation protocols for semaglutide and tirzepatide were specifically designed to manage this. For most patients, GI tolerance is not a reason to choose a less effective drug.
There is one scenario where lixisenatide's short-acting profile offers a genuine advantage: patients who experience persistent nausea throughout the day on long-acting GLP-1 drugs may find that a short-acting option producing a brief, predictable GI window is easier to manage. This is a real clinical consideration, even if it applies to a small fraction of patients.
Where Lixisenatide Still Has a Role
It's a niche, but it's a real one.
Post-meal glucose management is the strongest indication. In a patient whose fasting glucose is reasonably well-controlled on basal insulin but whose post-meal spikes remain problematic, lixisenatide's targeted gastric emptying effect can be additive without dramatically altering the overall treatment regimen. This combination — basal insulin plus short-acting GLP-1 agonist — is supported by GETGOAL trial data and represents a legitimate place in type 2 diabetes management.
The combination product iGlarLixi (brand name: Soliqua) makes this explicit: it combines insulin glargine with lixisenatide in a single pen, allowing both to be administered together. Soliqua remains available and prescribed, which keeps lixisenatide clinically relevant even as standalone Adlyxin prescriptions decline.
Sanofi's Broader GLP-1 Strategy
Sanofi isn't standing still on GLP-1 innovation.
In partnership with Regeneron, Sanofi is developing SAR441255 — a triple agonist targeting GLP-1, GIP, and glucagon receptors. This is the same strategic direction Eli Lilly is pursuing with retatrutide: three-receptor activation to push weight loss beyond what dual agonism achieves. Adding glucagon receptor agonism to the mix introduces a direct energy expenditure component — essentially signaling fat mobilization in addition to appetite suppression.
SAR441255 is in Phase 1/2 development. Regeneron's drug discovery platform, combined with Sanofi's clinical development and commercial infrastructure, gives this compound a credible pathway. Whether it delivers results comparable to Lilly's retatrutide Phase 2 data (24.2% weight loss at 48 weeks) remains to be seen.
The strategic picture tells you something important: even a company whose current GLP-1 drug isn't competitive on weight loss recognizes that the next generation of these drugs is likely to be defined by multi-receptor agonism, and they're investing accordingly.
Understanding Adlyxin in the Context of the Whole Drug Class
Lixisenatide is the contrast agent that sharpens the whole picture.
When you understand why a short-acting GLP-1 agonist produces modest weight loss and targeted post-meal glucose control, you understand why long-acting ones produce the dramatic results that made this drug class famous. The mechanism isn't binary — there's a spectrum of activity driven by how long the drug stays in the body and how continuously it activates the receptor. That spectrum matters for matching drug to patient.
| Feature | Lixisenatide (Adlyxin) | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) |
|---|---|---|---|
| Duration | Short-acting (hours) | Long-acting (weekly) | Long-acting (weekly) |
| Receptor target | GLP-1 only | GLP-1 only | GLP-1 + GIP |
| Postprandial glucose effect | Strong | Moderate | Moderate |
| Fasting glucose effect | Modest | Strong | Strong |
| Weight loss (avg) | ~2–3 kg | ~5–15% body weight | ~15–22.5% body weight |
| CV outcomes data | Neutral (ELIXA) | Benefit shown (LEADER for liraglutide; SELECT for semaglutide) | Pending long-term data |
Frequently Asked Questions
Is Adlyxin (lixisenatide) still available in the U.S.?
Yes, lixisenatide is still FDA-approved and available as Adlyxin in standalone form and as part of iGlarLixi (Soliqua), a combination product with insulin glargine. Prescribing volume has declined significantly as semaglutide and tirzepatide dominate new prescriptions, but it remains an option in the treatment algorithm for type 2 diabetes.
Why doesn't Adlyxin cause as much weight loss as Ozempic?
Duration of action is the core reason. Semaglutide (Ozempic) is engineered to last about a week in the body, producing continuous GLP-1 receptor activation that suppresses appetite around the clock. Lixisenatide clears within hours of injection. The sustained appetite suppression that drives significant weight loss requires continuous receptor activity — which short-acting drugs don't provide.
What is Sanofi's pipeline for GLP-1 drugs?
Sanofi's most notable GLP-1 pipeline asset is SAR441255, developed in partnership with Regeneron. It is a triple agonist targeting GLP-1, GIP, and glucagon receptors — similar in concept to Lilly's retatrutide. SAR441255 is in early clinical development. Sanofi also markets Soliqua (insulin glargine/lixisenatide combination), which keeps lixisenatide commercially active in an adjunct role.
Is Adlyxin good for weight loss?
No, not in any competitive sense. Clinical trial data shows average weight loss of approximately 2–3 kg with lixisenatide — meaningful as a secondary benefit in T2D management, but not a viable option for someone whose primary goal is significant body weight reduction. For that goal, the evidence points clearly to semaglutide or tirzepatide.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment.
